Biospace news

Syndicate content
RSS Feed for Biotech, Pharmaceutical and Clinical Research News | BioSpace (Generated by New Sloth)
Updated: 1 day 23 hours ago

2023 Year in Review: Biopharma Takes One Step Forward, Two Steps Back

Fri, 12/22/2023 - 02:00
2023 Year in Review: Biopharma Takes One Step Forward, Two Steps Back 12/22/2023

Alternative Funding Strategies to Discuss at JPM

Fri, 12/22/2023 - 02:00
Alternative Funding Strategies to Discuss at JPM 12/22/2023

BMS Closes the Year with $14B Karuna Buy to Bolster Neuro Portfolio

Fri, 12/22/2023 - 02:00
BMS Closes the Year with $14B Karuna Buy to Bolster Neuro Portfolio 12/22/2023

AstraZeneca, Ionis Get FDA Approval for hATTR-PN Therapy

Fri, 12/22/2023 - 02:00
AstraZeneca, Ionis Get FDA Approval for hATTR-PN Therapy 12/22/2023

Jazz’s Future in PTSD Left Uncertain Following Mid-Stage Trial Failure

Fri, 12/22/2023 - 02:00
Jazz’s Future in PTSD Left Uncertain Following Mid-Stage Trial Failure 12/22/2023

Three Companies Relent to FTC Demands, Delist Patents from FDA’s Orange Book

Fri, 12/22/2023 - 02:00
Three Companies Relent to FTC Demands, Delist Patents from FDA’s Orange Book 12/22/2023

AbbVie, Alpine Agree to End Phase II Lupus Trial Early and Slash Option Exercise Fee

Fri, 12/22/2023 - 02:00
AbbVie, Alpine Agree to End Phase II Lupus Trial Early and Slash Option Exercise Fee 12/22/2023

Lilly, Fauna Bio Ink Potential $494M Deal to Find Obesity Drug Targets

Fri, 12/22/2023 - 02:00
Lilly, Fauna Bio Ink Potential $494M Deal to Find Obesity Drug Targets 12/22/2023

BioMarin and Elliott Investment Strike Deal, Add New Board Seats

Fri, 12/22/2023 - 02:00
BioMarin and Elliott Investment Strike Deal, Add New Board Seats 12/22/2023

A World War II-Era Company Reshapes Itself as a Biotech Powerhouse

Fri, 12/22/2023 - 02:00
A World War II-Era Company Reshapes Itself as a Biotech Powerhouse 12/22/2023

Headed to JPM? Here Are Some Tips to Make the Most of It

Fri, 12/22/2023 - 02:00
Headed to JPM? Here Are Some Tips to Make the Most of It 12/22/2023

FDA Weighs Gene-Editing Treatments’ Curative Possibilities Against Potential Risks

Fri, 12/22/2023 - 02:00
FDA Weighs Gene-Editing Treatments’ Curative Possibilities Against Potential Risks 12/22/2023

First Rett Treatment Offers Hope to Morell Family

Fri, 12/22/2023 - 02:00
First Rett Treatment Offers Hope to Morell Family 12/22/2023

Biotech Bankruptcies Skyrocket

Fri, 12/22/2023 - 02:00
Biotech Bankruptcies Skyrocket 12/22/2023

6 Drugs Approved Despite Failed Trials or Minimal Data

Fri, 12/22/2023 - 02:00
6 Drugs Approved Despite Failed Trials or Minimal Data 12/22/2023

Biopharma Layoff Tracker 2023: Aclaris, Asher, Atara and More Cut Staff

Fri, 12/22/2023 - 02:00
Biopharma Layoff Tracker 2023: Aclaris, Asher, Atara and More Cut Staff 12/22/2023

FDA Decisions: AstraZeneca and Ionis Gain Approval for Self-Administered hATTR-PN Treatment

Fri, 12/22/2023 - 02:00
FDA Decisions: AstraZeneca and Ionis Gain Approval for Self-Administered hATTR-PN Treatment 12/22/2023

GSK Inks Potential $1.7B ADC Deal with China’s Hansoh Pharma

Wed, 12/20/2023 - 02:00
GSK Inks Potential $1.7B ADC Deal with China’s Hansoh Pharma 12/20/2023

Argenx Nixes Efgartigimod’s Development in Pemphigus After Phase III Flop

Wed, 12/20/2023 - 02:00
Argenx Nixes Efgartigimod’s Development in Pemphigus After Phase III Flop 12/20/2023

Chiesi’s $1.25B Amryt Buy Pays Off with FDA Approval of Filsuvez

Wed, 12/20/2023 - 02:00
Chiesi’s $1.25B Amryt Buy Pays Off with FDA Approval of Filsuvez 12/20/2023